Clinical Trial Update: Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study [Phase 1]

View source ↗

Summary

Phase 1 PET imaging study to evaluate brain uptake of GSK1034702 in individuals with cognitive disorders; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Disorders

Drugs mentioned

• GSK1034702

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cognitive Disorders | Phase 1 | Status: COMPLETED